Want to see CRSP full AI Analyst Report?
Top Page
Crispr Therapeutics AG
(NASDAQ:CRSP)
Select Model
Select Model
Rating:46Neutral
Price Target:
$49.00
▲(5.29% Upside)
Action:Reiterated
Date:08/04/26
The score is held down primarily by weak operating fundamentals and cash burn (negative margins, large losses, and materially negative free cash flow) despite a comparatively stronger balance sheet. Technicals add a modest headwind with price below key moving averages and negative MACD. Valuation is not supportive due to losses (negative P/E) and no dividend yield, while the recent governance/incentive-plan approvals provide a smaller offset via improved flexibility and retention tools.
Positive Factors
Balance Sheet Strength
CRISPR Therapeutics’ balance sheet retains sizable equity relative to debt, providing a structural cushion to fund clinical programs and operations. This financial flexibility reduces short-term insolvency risk, enables continued R&D investment, and supports execution across multi-year development timelines.
Negative Factors
Sustained Cash Burn
Trailing-twelve-month operating and free cash flow are materially negative with deterioration versus prior year, indicating persistent cash burn. This ongoing funding gap creates multi-quarter financing needs, which can force dilution or higher-cost capital and constrain long-term program pacing.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
CRISPR Therapeutics’ balance sheet retains sizable equity relative to debt, providing a structural cushion to fund clinical programs and operations. This financial flexibility reduces short-term insolvency risk, enables continued R&D investment, and supports execution across multi-year development timelines.
Read all positive factors
Crispr Therapeutics AG Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Data provided by:
The Fly
The FlyCrispr Therapeutics AG (CRSP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.63B
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)―
Beta (1Y)1.87
Revenue Growth-89.11%
EPS Growth-37.55%
CountryUS
Employees393
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.76
Shares Outstanding96,448,790
10 Day Avg. Volume1,726,236
30 Day Avg. Volume1,677,481
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.45
Price to Sales (P/S)1343.50
P/FCF Ratio-13.63
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.64Price Target Upside56.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.47
Revenue Forecast (FY)$40.93M
Crispr Therapeutics AG Business Overview & Revenue Model
Company Description
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-assoc...
How the Company Makes Money
CRISPR Therapeutics primarily generates revenue from (1) collaboration and partnership arrangements and (2) product-related economics where applicable. A major driver has been its collaboration with Vertex Pharmaceuticals for the CRISPR/Cas9-edite...
Crispr Therapeutics AG Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
64
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.39M | 3.51M | 35.00M | 370.00M | 436.00K | 913.08M |
| Gross Profit | -205.49M | -229.45M | -75.25M | 239.75M | -109.81M | 811.90M |
| EBITDA | -454.00M | -558.49M | -343.41M | -130.88M | -626.33M | 397.48M |
| Net Income | -451.14M | -581.60M | -366.25M | -153.61M | -650.17M | 377.66M |
Balance Sheet | ||||||
| Total Assets | 2.65B | 2.27B | 2.24B | 2.23B | 2.24B | 2.75B |
| Cash, Cash Equivalents and Short-Term Investments | 2.36B | 1.98B | 1.90B | 1.69B | 1.82B | 2.38B |
| Total Debt | 783.75M | 394.91M | 223.69M | 238.63M | 244.02M | 225.03M |
| Total Liabilities | 904.22M | 343.43M | 309.95M | 346.77M | 367.58M | 352.42M |
| Stockholders Equity | 1.75B | 1.92B | 1.93B | 1.88B | 1.88B | 2.40B |
Cash Flow | ||||||
| Free Cash Flow | -480.73M | -345.93M | -144.68M | -269.85M | -532.93M | 457.27M |
| Operating Cash Flow | -478.48M | -345.01M | -142.77M | -260.38M | -495.74M | 538.97M |
| Investing Cash Flow | -959.17M | -31.80M | -280.48M | 374.65M | -258.65M | -1.04B |
| Financing Cash Flow | 1.60B | 426.03M | 331.98M | 62.66M | 38.59M | 250.94M |
Crispr Therapeutics AG Technical Analysis
Positive
46.54
Price Trends
52.34
Positive
51.68
Positive
53.77
Negative
Market Momentum
-0.73
Negative
55.64
Neutral
92.72
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Positive. The current price of 46.54 is below the 20-day moving average (MA) of 49.42, below the 50-day MA of 52.34, and below the 200-day MA of 53.77, indicating a neutral trend. The MACD of -0.73 indicates Negative momentum. The RSI at 55.64 is Neutral, neither overbought nor oversold. The STOCH value of 92.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRSP.
Crispr Therapeutics AG Risk Analysis
Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Crispr Therapeutics AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $8.51B | -28.88 | -25.02% | ― | -12.58% | -15.21% | |
53 Neutral | $1.49B | -3.02 | -57.27% | ― | 45.04% | 32.42% | |
52 Neutral | $3.45B | -13.64 | -24.91% | ― | 56.70% | -13.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $4.63B | -7.72 | -30.88% | ― | -89.11% | -37.55% | |
44 Neutral | $2.63B | -39.88 | -7.70% | ― | 157.97% | 86.11% |
* Healthcare Sector Average
CRSP
Crispr Therapeutics AG
52.45
-3.89
-6.90%
NTLA
Intellia Therapeutics
10.97
-0.40
-3.52%
BEAM
Beam Therapeutics
27.07
8.77
47.92%
LEGN
Legend Biotech
19.05
-18.61
-49.42%
KYMR
Kymera Therapeutics
105.48
64.13
155.09%
Crispr Therapeutics AG Corporate Events
Business Operations and StrategyFinancial DisclosuresShareholder Meetings
Shareholders Approve New Incentive Plan and Governance Measures
Positive
Jun 4, 2026
On June 4, 2026, CRISPR Therapeutics shareholders approved a new 2026 Stock Option and Incentive Plan that rolls over unused shares from prior equity plans and allows a broad range of stock- and cash-based awards, reinforcing the company’s a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.